Center-Authored Papers

Filters: Keyword is Estrogens  [Clear All Filters]
A
Atkinson C, Newton KM, Stanczyk FZ, Westerlind KC, Li L, Lampe JW.  2008.  Daidzein-metabolizing phenotypes in relation to serum hormones and sex hormone binding globulin, and urinary estrogen metabolites in premenopausal women in the United States.. Cancer causes & control : CCC. 19(10):1085-93. Abstract
B
Bea JW, Zhao Q, Cauley JA, LaCroix AZ, Bassford T, Lewis CE, Jackson RD, Tylavsky FA, Chen Z.  2011.  Effect of hormone therapy on lean body mass, falls, and fractures: 6-year results from the Women's Health Initiative hormone trials.. Menopause (New York, N.Y.). 18(1):44-52. Abstract
Bray PF, Larson JC, LaCroix AZ, Manson J, Limacher MC, Rossouw JE, Lasser NL, Lawson WE, Stefanick ML, Langer RD et al..  2008.  Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events.. The American journal of cardiology. 101(11):1599-1605. Abstract
C
Chen Z, Beck TJ, Cauley JA, Lewis CE, LaCroix AZ, Bassford T, Wu G, Sherrill D, Going S.  2008.  Hormone therapy improves femur geometry among ethnically diverse postmenopausal participants in the Women's Health Initiative hormone intervention trials.. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 23(12):1935-45. Abstract
Chlebowski RT, Anderson G, Pettinger M, Lane D, Langer RD, Gilligan MA, Gillian MA, Walsh BW, Chen C, McTiernan A.  2008.  Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy.. Archives of internal medicine. 168(4):370-7;quiz345. Abstract
Chlebowski RT, Prentice RL.  2008.  Menopausal hormone therapy in BRCA1 mutation carriers: uncertainty and caution.. Journal of the National Cancer Institute. 100(19):1341-3.
D
Diergaarde B, Potter JD, Jupe ER, Manjeshwar S, Shimasaki CD, Pugh TW, Defreese DC, Gramling BA, Evans I, White E.  2008.  Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 17(7):1751-9. Abstract
E
Edlefsen KL, Jackson RD, Prentice RL, Janssen I, Rajkovic A, O'Sullivan MJ, Anderson G.  2010.  The effects of postmenopausal hormone therapy on serum estrogen, progesterone, and sex hormone-binding globulin levels in healthy postmenopausal women.. Menopause (New York, N.Y.). 17(3):622-9. Abstract
Epplein M, Reed SD, Voigt LF, Newton KM, Holt VL, Weiss NS.  2009.  Endometrial hyperplasia risk in relation to recent use of oral contraceptives and hormone therapy.. Annals of epidemiology. 19(1):1-7. Abstract
Epplein M, Reed SD, Voigt LF, Newton KM, Holt VL, Weiss NS.  2008.  Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history.. American journal of epidemiology. 168(6):563-70;discussion571-6. Abstract
H
Hooper LE, Foster-Schubert KE, Weigle DS, Sorensen B, Ulrich CM, McTiernan A.  2010.  Frequent intentional weight loss is associated with higher ghrelin and lower glucose and androgen levels in postmenopausal women.. Nutrition research (New York, N.Y.). 30(3):163-70. Abstract
L
LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, Margolis KL, Stefanick ML, Brzyski R, Curb DJ et al..  2011.  Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial.. JAMA : the journal of the American Medical Association. 305(13):1305-14. Abstract
Li CI, Malone KE, Porter PL, Lawton TJ, Voigt LF, Cushing-Haugen KL, Lin MG, Yuan X, Daling JR.  2008.  Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 17(1):43-50. Abstract
M
Maalouf NM, Sato AH, Welch BJ, Howard BV, Cochrane BB, Sakhaee K, Robbins JA.  2010.  Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials.. Archives of internal medicine. 170(18):1678-85. Abstract
Manson JE, Chlebowski RT, Aragaki AK.  2014.  Hormone therapy use and outcomes in the Women's Health Initiative trials--reply.. JAMA : the journal of the American Medical Association. 311(4):417-8.
Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ et al..  2013.  Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.. JAMA : the journal of the American Medical Association. 310(13):1353-68. Abstract
P
Pitteri SJ, Amon LM, Busald Buson T, Zhang Y, Johnson MM, Chin A, Kennedy J, Wong C-H, Zhang Q, Wang H et al..  2010.  Detection of elevated plasma levels of epidermal growth factor receptor before breast cancer diagnosis among hormone therapy users.. Cancer research. 70(21):8598-606. Abstract
Pitteri SJ, Hanash SM.  2011.  Confounding effects of hormone replacement therapy in protein biomarker studies.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 20(1):134-9. Abstract
Prentice RL, Chlebowski RT, Stefanick ML, Manson JE, Langer RD, Pettinger M, Hendrix SL, Hubbell AF, Kooperberg C, Kuller LH et al..  2008.  Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study.. American journal of epidemiology. 167(12):1407-15. Abstract
Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, Jackson RD, Johnson KC, Kuller LH, Lane DS, Wactawski-Wende J et al..  2009.  Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause.. American journal of epidemiology. 170(1):12-23. Abstract
Prentice RL, Huang Y, Hinds DA, Peters U, Pettinger M, Cox DR, Beilharz E, Chlebowski RT, Rossouw JE, Caan B et al..  2009.  Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 18(11):3079-85. Abstract
Prentice RL.  2008.  Data analysis methods and the reliability of analytic epidemiologic research.. Epidemiology (Cambridge, Mass.). 19(6):785-8;discussion789-93. Abstract
R
Reding KW, Doody DR, McTiernan A, Hsu L, Davis S, Daling JR, Porter PL, Malone KE.  2011.  Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer.. Breast cancer research and treatment. 126(3):749-61. Abstract
Robinson JG, Wallace R, Limacher M, Ren H, Cochrane BB, Wassertheil-Smoller S, Ockene JK, Blanchette PL, Ko MG.  2008.  Cardiovascular risk in women with non-specific chest pain (from the Women's Health Initiative Hormone Trials).. The American journal of cardiology. 102(6):693-9. Abstract
Rohan TE, Negassa A, Chlebowski RT, Lasser NL, McTiernan A, Schenken RS, Ginsberg M, Wassertheil-Smoller S, Page DL.  2008.  Estrogen plus progestin and risk of benign proliferative breast disease.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 17(9):2337-43. Abstract